Phenyl isocyanate → 1-[4-Methyl-3-(1-methyl-1H-pyrazolo[3,4-c]pyridin-4-ylethynyl)-phenyl]-3-phenyl-urea
反応式
[CH3:1][C:2]1[CH:7]=[CH:6][C:5]([NH2:8])=[CH:4][C:3]=1[C:9]#[C:10][C:11]1[CH:16]=[N:15][CH:14]=[C:13]2[N:17]([CH3:20])[N:18]=[CH:19][C:12]=12.[C:21]1([N:27]=[C:28]=[O:29])[CH:26]=[CH:25][CH:24]=[CH:23][CH:22]=1>C(Cl)Cl>[CH3:1][C:2]1[CH:7]=[CH:6][C:5]([NH:8][C:28]([NH:27][C:21]2[CH:26]=[CH:25][CH:24]=[CH:23][CH:22]=2)=[O:29])=[CH:4][C:3]=1[C:9]#[C:10][C:11]1[CH:16]=[N:15][CH:14]=[C:13]2[N:17]([CH3:20])[N:18]=[CH:19][C:12]=12参加物
4
実験手順
In analogy to GP 5, 200 mg of 4-methyl-3-(1-methyl-1H-pyrazolo[3,4-c]pyridin-4-ylethynyl)-phenylamine (Intermediate 3.2, 0.4 mmol, 1 eq.) were treated with 47 μL phenyl isocyanate (0.44 mmol, 1.1 eq.) in 4 mL DCM at rt. Aqueous work-up followed by HPLC purification provided the target compound.